Bristol-Myers Squibb (BMS) is a major American pharma company with leading franchises in oncology (Opdivo, Revlimid) and cardiology (Eliquis). The Celgene acquisition (2019) significantly expanded its oncology and immunology portfolio.
Oncology, Cardiology, Immunology, Neuroscience
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Eliquis (apixaban) | Cardiology | $12.2B |
| Opdivo (nivolumab) | Oncology | $9.0B |
| Revlimid (lenalidomide) | Oncology (MM) | $6.0B |
| Pomalyst (pomalidomide) | Oncology (MM) | $3.5B |
| Sprycel (dasatinib) | Oncology (CML) | $2.0B |
| Reblozyl (luspatercept) | Rare diseases (MDS, beta-thalassemia) | $1.0B |
BMS is the #9 pharma company. Eliquis and Opdivo are the twin pillars, each generating $9-12B. Revlimid generic erosion (2024) is a headwind, but CAR-T therapies (Breyanzi, Abecma) and mavacamten provide growth.
Revenue projected at $43-46B through 2026. Revlimid decline offset by Opdivo expansion and Eliquis growth. Eliquis generic entry (2026-2028) is the next major cliff. CAR-T and mavacamten represent diversification.
Bristol-Myers Squibb 2023 Annual Report (Form 10-K). Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.